Richard Peck
Gründer bei Cellestia Biotech AG
Profil
Richard Peck is the founder of Cellestia Biotech AG, which was founded in 2014.
He held the title of Head-Regulatory Affairs at the company.
Dr. Peck's former job was as Head-Regulatory Affairs at Finox Biotech AG.
Aktive Positionen von Richard Peck
Unternehmen | Position | Beginn |
---|---|---|
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Gründer | 01.01.2014 |
Ehemalige bekannte Positionen von Richard Peck
Unternehmen | Position | Ende |
---|---|---|
Finox Biotech AG
Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland. | General Counsel | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Finox Biotech AG
Finox Biotech AG Medical/Nursing ServicesHealth Services Finox AG specializes in developing fertility drugs. Its products include BEMFOLA, a recombinant-human follicle-stimulating hormone. The company was founded by Michel Wilhelm in 2007 and is headquartered in Burgdorf, Switzerland. | Health Services |
Cellestia Biotech AG
Cellestia Biotech AG Pharmaceuticals: MajorHealth Technology Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland. | Health Technology |